« Return to News | R&D Trends

Foundation Medicine, AstraZeneca collaborate on genomic profiling for targeted cancer therapies

Tuesday, November 13, 2012 09:23 AM

Foundation Medicine, a molecular information company based in Cambridge, Mass., has formed a multi-year collaboration with global biopharmaceutical company AstraZeneca to identify alterations found in cancer-related tumor genes that may predict a person's response or resistance to targeted medicines.

Working with Foundation Medicine to reveal these genomic alterations may help AstraZeneca to research new medicines for people with cancer. Foundation Medicine was also granted right of first negotiation for the development of potential diagnostic products.

"Our scientific understanding of cancer and the pathways driving tumor growth enables us to focus on which people are most likely to respond to our medicines,” said Susan Galbraith, vice president and head of oncology innovative medicines unit, AstraZeneca. “This collaboration with Foundation Medicine will help us to identify tumor-specific defects and alterations that can be used for patient segmentation."

Michael J. Pellini, M.D., president and CEO, Foundation Medicine, said, “AstraZeneca has a strong commitment to understanding the patient-to-patient variations that may impact the efficacy of therapeutic candidates. We are helping companies like AstraZeneca achieve deeper insight into their programs and trials with our unique cancer expertise and our ability to provide genomic information that can impact clinical treatment decisions. Together, we expect to enable a more individualized, targeted approach to cancer drug development and clinical trials.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.